Literature DB >> 22079741

Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models.

Anabel José1, Luciano Sobrevals, Antoni Ivorra, Cristina Fillat.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) therapies show limited success. Irreversible electroporation (IRE) is an innovative loco-regional therapy in which high-voltage pulses are applied to induce plasma membrane defects leading to cellular death. In the present study we evaluated the feasibility of IRE against PDAC. IRE treatment exhibited significant antitumor effects and prolonged survival in mice with orthotopic xenografts. Extensive tumor necrosis, reduced tumor cell proliferation and disruption of microvessels were observed at different days post-IRE. Animals had transient increases in transaminases, amylase and lipase enzymes that normalized at 24h post-IRE. These results suggest that IRE could be an effective treatment for locally advanced pancreatic tumors.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079741     DOI: 10.1016/j.canlet.2011.11.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  Intracellular tracking of single-plasmid DNA particles after delivery by electroporation.

Authors:  Christelle Rosazza; Annette Buntz; Thorsten Rieß; Dominik Wöll; Andreas Zumbusch; Marie-Pierre Rols
Journal:  Mol Ther       Date:  2013-08-14       Impact factor: 11.454

Review 2.  Irreversible electroporation: evolution of a laboratory technique in interventional oncology.

Authors:  Amy R Deipolyi; Alexander Golberg; Martin L Yarmush; Ronald S Arellano; Rahmi Oklu
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

3.  Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy.

Authors:  Maria Paola Belfiore; Alfonso Reginelli; Nicola Maggialetti; Mattia Carbone; Sabrina Giovine; Antonella Laporta; Fabrizio Urraro; Valerio Nardone; Roberta Grassi; Salvatore Cappabianca; Luca Brunese
Journal:  Med Oncol       Date:  2020-04-09       Impact factor: 3.064

Review 4.  Electroporation and Immunotherapy-Unleashing the Abscopal Effect.

Authors:  Tobias Freyberg Justesen; Adile Orhan; Hans Raskov; Christian Nolsoe; Ismail Gögenur
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

5.  OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model.

Authors:  Qi-Wei Zhang; Xiao-Xia Guo; Yu Zhou; Qing-Bing Wang; Qin Liu; Zhi-Yuan Wu; Xiao-Yi Ding
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.

Authors:  Maria Victoria Maliandi; Ana Mato-Berciano; Luciano Sobrevals; Gaël Roué; Anabel José; Cristina Fillat
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401

7.  Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts.

Authors:  Anabel José; Luciano Sobrevals; Juan Miguel Camacho-Sánchez; Meritxell Huch; Núria Andreu; Eduard Ayuso; Pilar Navarro; Ramon Alemany; Cristina Fillat
Journal:  Oncotarget       Date:  2013-01

8.  Irreversible electroporation of the liver: is there a safe limit to the ablation volume?

Authors:  P Sánchez-Velázquez; Q Castellví; A Villanueva; R Quesada; C Pañella; M Cáceres; D Dorcaratto; A Andaluz; X Moll; M Trujillo; J M Burdío; E Berjano; L Grande; A Ivorra; F Burdío
Journal:  Sci Rep       Date:  2016-04-01       Impact factor: 4.379

Review 9.  Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies.

Authors:  Sabrina Bimonte; Maddalena Leongito; Vincenza Granata; Antonio Barbieri; Vitale Del Vecchio; Michela Falco; Aurelio Nasto; Vittorio Albino; Mauro Piccirillo; Raffaele Palaia; Alfonso Amore; Raimondo di Giacomo; Secondo Lastoria; Sergio Venanzio Setola; Roberta Fusco; Antonella Petrillo; Francesco Izzo
Journal:  Radiol Oncol       Date:  2016-02-16       Impact factor: 2.991

Review 10.  Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma.

Authors:  Junjie Li; Fengyong Liu; Sanjay Gupta; Chun Li
Journal:  Theranostics       Date:  2016-06-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.